The extension granted by Nasdaq is a positive development for Glucotrack as it provides additional time to address the listing compliance issues without facing immediate delisting. This news may instill confidence in investors and could lead to a short-term positive impact on the stock price. However, the underlying issues causing the non-compliance still need to be resolved, which is why the importance is not at the maximum level.